These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11948260)

  • 1. Clinical applications of (18)F-FDG in oncology.
    Nabi HA; Zubeldia JM
    J Nucl Med Technol; 2002 Mar; 30(1):3-9; quiz 10-1. PubMed ID: 11948260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Positron-emission tomography in oncology].
    Zaplatnikov K; Menzel C; Döbert N; Diehl M; Hamscho N; Grünwald F
    Klin Med (Mosk); 2003; 81(12):13-21. PubMed ID: 14971150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical role of positron emission tomography in oncology.
    Bomanji JB; Costa DC; Ell PJ
    Lancet Oncol; 2001 Mar; 2(3):157-64. PubMed ID: 11902566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.
    Delbeke D
    J Nucl Med; 1999 Apr; 40(4):591-603. PubMed ID: 10210218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effective PET scans in oncology].
    Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Várady E; Galuska L; Trón L; Esik O
    Orv Hetil; 2002 May; 143(21 Suppl 3):1255-61. PubMed ID: 12077909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer.
    Kubota K; Matsuno S; Morioka N; Adachi S; Koizumi M; Seto H; Kojo M; Nishioka S; Nishimura M; Yamamoto H
    Ann Nucl Med; 2015 Jun; 29(5):431-41. PubMed ID: 25812534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
    Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
    Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
    J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effective PET investigations in oncology].
    Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Galuska L; Trón L; Esik O
    Magy Onkol; 2002; 46(3):203-23. PubMed ID: 12368917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostic value of positron emission tomography (PET) in clinical oncology].
    Czech N; Brenner W; Kampen WU; Henze E
    Dtsch Med Wochenschr; 2000 May; 125(18):565-7. PubMed ID: 10835983
    [No Abstract]   [Full Text] [Related]  

  • 11. Utility of 18F-FDG PET in evaluating cancers of lung.
    Acker MR; Burrell SC
    J Nucl Med Technol; 2005 Jun; 33(2):69-74; quiz 75-7. PubMed ID: 15930019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical applications of PET in oncology.
    Rohren EM; Turkington TG; Coleman RE
    Radiology; 2004 May; 231(2):305-32. PubMed ID: 15044750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET imaging in oncology.
    Bar-Shalom R; Valdivia AY; Blaufox MD
    Semin Nucl Med; 2000 Jul; 30(3):150-85. PubMed ID: 10928381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.
    Kostakoglu L; Goldsmith SJ
    J Nucl Med; 2003 Feb; 44(2):224-39. PubMed ID: 12571214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET/CT in oncology: a major technology for cancer care.
    Ell PJ
    Chang Gung Med J; 2005 May; 28(5):274-83. PubMed ID: 16086542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of [18F]-FDG-PET on medical decision making in oncology: evaluation by the referring physicians during the opening year].
    Talbot JN; Rain JD; Meignan M; Askienazy S; Grall Y; Bok B; Misset JL
    Bull Cancer; 2002 Mar; 89(3):313-21. PubMed ID: 11940470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perineural spread of melanoma demonstrated by F-18 FDG PET With MRI and pathologic correlation.
    Lee TJ; Glastonbury CM; Buckley AF; Eisele DW; Hawkins RA
    Clin Nucl Med; 2008 Feb; 33(2):106-8. PubMed ID: 18209529
    [No Abstract]   [Full Text] [Related]  

  • 19. In-111 DTPA-octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18 FDG positron emission tomography and extensive conventional radiographic imaging.
    Sarlis NJ; Gourgiotis L; Guthrie LC; Galen B; Skarulis MC; Shawker TH; Patronas NJ; Reynolds JC
    Clin Nucl Med; 2003 Mar; 28(3):208-17. PubMed ID: 12592128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000.
    Reske SN; Kotzerke J
    Eur J Nucl Med; 2001 Nov; 28(11):1707-23. PubMed ID: 11702115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.